New York, US and Vienna, Austria, November 15, 2018 – HOOKIPA Pharma Inc. (“HOOKIPA”), a company developing an innovative class of immunotherapies for oncology and infectious diseases using its proprietary arenavirus technologies, today announced that it has been recognized by Lifestars Awards as the winner of the 2018 EU Deal of the Year category.
On June 5, HOOKIPA announced a research collaboration and licensing agreement with Gilead. This agreement grants Gilead exclusive rights to HOOKIPA´s proprietary TheraT® and Vaxwave® arenavirus vector-based immunization technologies for two major chronic infectious disease indications, hepatitis B virus (HBV) and human immunodeficiency virus (HIV). The deal expands the relationship between HOOKIPA and Gilead following Gilead’s participation in Hookipa’s Series C financing in December 2017. Under the terms of the agreement, Gilead provided HOOKIPA an upfront payment of $10 million. Additionally, HOOKIPA became eligible to receive milestone payments based upon the achievement of specified development, regulatory, and commercial milestones up to a total of over $400 million. HOOKIPA will also be eligible to receive tiered royalties on any future net sales of vaccines resulting from the agreement. Gilead will fund all research and development activities.
“I am honored to accept this award on behalf of our dedicated team and grateful to Lifestars Awards for recognizing our commitment to cure HIV and HBV by eliminating all virus particles including those in infected cells” said Torsten Mummenbrauer, Senior Vice President of Business Development of HOOKIPA.
In 2016, there were approximately 36.7 million people living with HIV/AIDS and 257 million people are living with hepatitis B virus infection around the world.
- END -
HOOKIPA Pharma Inc. is a clinical stage company developing medicines designed to prevent and potentially cure infectious diseases and cancer. With this goal in mind, we created proprietary technologies to reprogram and stimulate the immune system.
Our proprietary Arenavirus technologies, Vaxwave®, a replication-deficient viral vector, and TheraT®, a replication-attenuated vector, are designed to induce potent antigen specific CD8+ T cells and pathogen-neutralizing antibodies. Both, Vaxwave® and TheraT®, are designed to be administered repeatedly while maintaining an immune response. TheraT® has the potential to induce CD8+ T cell responses to tumor antigens and reach frequencies and potencies matching or exceeding those observed after adoptive T cell therapy. Our “off-the-shelf” viral vectors target dendritic cells in vivo to activate the immune system. In immuno-oncology, this mechanism enables the immune system to fight solid tumors systemically.
We have successfully completed a Phase 1 trial of a Vaxwave®-based prophylactic vaccine to protect against CMV infections. A Phase II trial in solid organ transplant patients is about to start. Alongside, we have forged a partnership with Gilead Sciences Inc. to jointly research and develop functional cures for HIV and Hepatitis B infections. We are building a proprietary immuno-oncology pipeline by targeting TheraT® towards HPV+ head and neck squamous cell carcinoma and prostate cancer.
Find out more about HOOKIPA online at www.hookipapharma.com.
About Lifestar Awards
The Lifestars Awards brings together 300 global life science leaders, investors and deal makers, and is a celebration of the success stories, innovations, transformational deals and the people, teams and organisations that have played such a critical role in the advancement of the industry over the last 12 months across Europe and the US. Lifestars is run in association with Jefferies, on the evening of the LSX Inv€$tival Showcase on 13 November. It forms a signature, evening networking function during the Jefferies Annual Healthcare Conference week in London, Europe's largest healthcare investment banking conference.
Gilead is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. It strives to transform and simplify care for people with life-threatening illnesses and is a world leader in innovative therapies against major viral diseases. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. Their team has helped transform HIV infection from a fatal and debilitating disease into a chronic, manageable condition. Gilead continues to develop new options to improve treatment and care over the course of a lifetime for diverse populations living with HIV around the world.
Issued for and on behalf of HOOKIPA Pharma Inc. by Instinctif Partners. For further information please contact:
Communications & Investor Relations Manager
Sue Charles/ Ashley Tapp
+44 (0)20 7457 2020